ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
Indivior PLC

Indivior PLC (INDV)

9.69
0.11
(1.15%)
마감 27 3월 5:00AM
9.69
0.00
(0.00%)
시간외 거래: 6:30AM

행사 가격매수가매도가최근 가격중간 가격가격 변동가격 변동 %거래량미결제 약정최근 거래
2.506.807.600.007.200.000.00 %00-
5.004.305.003.004.650.000.00 %01-
7.501.852.850.002.350.000.00 %00-
10.000.000.000.000.000.000.00 %00-
12.500.000.000.000.000.000.00 %00-
15.000.000.750.000.000.000.00 %00-
17.500.000.000.000.000.000.00 %00-

개인 투자자를 위한 전문가급 도구.

행사 가격매수가매도가최근 가격중간 가격가격 변동가격 변동 %거래량미결제 약정최근 거래
2.500.000.750.000.000.000.00 %00-
5.000.000.050.000.000.000.00 %00-
7.500.000.000.000.000.000.00 %00-
10.000.000.000.000.000.000.00 %00-
12.502.453.303.142.8750.000.00 %02-
15.000.000.000.000.000.000.00 %00-
17.500.000.000.000.000.000.00 %00-

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
PTPIPetros Pharmaceuticals Inc
US$ 0.1369
(136.85%)
1.59B
OSRHOSR Holdings Inc
US$ 3.69
(130.63%)
96.07M
VVPRVivoPower International PLC
US$ 4.2307
(87.20%)
143.02M
LXEHLixiang Education Holding Company Ltd
US$ 18.42
(77.12%)
432.15k
SURGSurgePays Inc
US$ 2.341
(69.64%)
69.74M
BACKIMAC Holdings Inc
US$ 0.071
(-64.50%)
1.22M
ACRVAcrivon Therapeutics Inc
US$ 2.53
(-53.06%)
1.88M
BHILBenson Hill Inc
US$ 0.2431
(-42.58%)
2.12M
TNONTenon Medical Inc
US$ 2.49
(-33.60%)
18.24M
HUMAHumacyte Inc
US$ 2.015
(-29.91%)
26.04M
PTPIPetros Pharmaceuticals Inc
US$ 0.1369
(136.85%)
1.59B
OCEAOcean Biomedical Inc
US$ 0.0837
(47.36%)
877.25M
LYTLytus Technologies Holdings PTV Ltd
US$ 0.0626
(23.72%)
319.83M
NVDANVIDIA Corporation
US$ 113.76
(-5.74%)
296.39M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 10.5499
(-10.97%)
239.93M

INDV Discussion

게시물 보기
Monksdream Monksdream 12 월 전
INDV over $20
👍️0
Renee Renee 2 년 전
IZQVF: effective Oct. 10,2022 a one for 5 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
👍️0
cash4 cash4 5 년 전
March 23, 2020
Statement on the Coronavirus and Global Supply of Medicines
Indivior is closely monitoring developments relating to COVID-19 (novel coronavirus) outbreak.
Our priority remains the ongoing supply of medicines to healthcare providers and patients, the
health and safety of our employees and the well-being of the patients we serve.
We are actively managing our global supply chains to minimize any potential disruption. Our
executive management and supply team are together working with internal and external business
partners and regulatory authorities to assess and mitigate the potential impact of COVID-19. We are
committed to helping ensure that patients will continue to have an ongoing supply of their
medication. Based on our assessment and environment we do not currently expect to have any
material supply interruptions.
We are also following guidelines provided by international health authorities and all global, national
and local government mandates regarding measures to keep our workforce and communities safe.
We have instituted a remote work policy for office and field-based staff leveraging all available
technology to ensure essential activities will continue to provide patients, healthcare providers and
other key stakeholders with the supports they need.
We will continue to monitor the situation closely, placing the needs of patients first at all times.
👍️0